ATA188 ‘Game Changing’ for Progressive MS & Ublituximab Superior to Aubagio

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads a news report on ATA188, a treatment targeting the Epstein-Barr virus which could be integral in treating progressive MS.

He also reads a news article reporting on how ublituximab works better than Aubagio at easing disability in patients with relapsing MS.
===================================
Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/
=====================================
To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/